G.A. IGNATENKO¹, A.Е. BAGRIY¹, O.A. PRIKOLOTA¹, A.V. PRIKOLOTA¹, I.S. MYKHAILICHENKO¹, I.A. GOLODNIKOV¹, E.E. GODOVICHENKO²

 ¹M. Gorky Donetsk National Medical University, Donetsk, Donetsk People’s Republic

² Central City Clinical Hospital No. 1, Donetsk, Donetsk People’s Republic

  Contact details:

Prikolota A.V. — PhD (medicine), Assistant Lecturer of the Department of Therapy, FIPO named after Prof. A.I. Dyadyk

Address: 16 Illicha Ave., 283003 Donetsk, Donetsk People’s Republic, tel.: + 7-949-312-79-45, e-mail: prikav@yandex.ru

The purpose — to compare the efficacy and safety of the use of two regimens for the use of renin-angiotensin system blockers — valsartan / sacubitril (V/C) and losartan in patients with diabetes mellitus (DM) type 2 in combination with chronic heart failure (HF) and low ejection fraction (EF) of the left ventricle (LV).

Material and methods. We observed 46 patients with type 2 diabetes. All these patients had previously suffered from myocardial infarction and had clinical manifestations of chronic HF class II-III with LV EF < 40%. All patients were recommended lifestyle changes, they received adequate hypoglycemic and organ-protective therapy. Two groups were distinguished: group A (16 patients, taking V/C at an initial dose of 100 mg/day, followed by titration to 400 mg/day) and group B (30 patients, taking losartan at an initial dose of 50 mg/day, with titration up to 150 mg/day). In the course of treatment and after 11 months, clinical and laboratory studies were performed, in dynamics, echocardiography with tissue Doppler, ultrasound of the brachiocephalic arteries, and a test with reactive hyperemia were performed.

Results. During treatment in group A, compared with group B, a more significant positive dynamics of clinical manifestations and the following studied parameters were noted: HOMA-IR and ΔHOMA-B indices, glycated hemoglobin levels, chronic HF class, LV EF, left atrial volume index, ratio of early diastolic velocity of transmitral blood flow to early diastolic velocity of the mitral valve ring, carotid intima-media complex thickness, and indexbrachial arteries resistivity; all changes are significant.

Conclusions. Combined neurohumoral blockade using V/S compared with losartan in patients with DM type 2 and chronic HF with low LV EF helped to have more positive changes in clinical-laboratory and instrumental indicators.

Key words: chronic heart failure, diabetes type 2, treatment.

REFERENCES

1. Mareev V.Yu., Fomin I.V., Ageev F.T. Clinical guidelines OSSN-RKO-RNMOT. Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya, 2018, no. 58 (6S), pp. 8–158 (in Russ.). DOI: 10.18087/cardio.2475
2. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC / T.A. McDonagh, M. Metra, M. Adamo [et al.]. European journal of heart failure, 2021, vol. 42 (36), pp. 3599–3726. DOI: 10.1093/eurheartj/ehab368
3. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes 2020. Diabetes Care, 2020, vol. 43 (l.1.), pp. S111–S134. DOI: 10.2337/dc20-s010
4. Cosentino F., Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 2020, vol. 41 (2), pp. 255–323. DOI: 10.1093/eurheartj/ehz486
5. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Type 2 diabetes mellitus in adults: clinical guidelines. Sakharnyy diabet, 2020, vol. 23, no. S2, pp. 4–102 (in Russ.).
6. GPJ Cosentino F., Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 2019, P. 1–69.
7. Jhund P.S., Fu M., Bayram E. et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J, 2015, vol. 36 (38), pp. 2576–84. DOI: 10.1093/eurheartj/ehv330. Epub 2015 Jul 31
8. Simpson J., Jhund P.S., Cardoso J.S. et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol., 2015, vol. 66 (19), pp. 2059–2071. DOI: 10.1016/j.jacc.2015.08.878
9. Gori M., Volterrani M., Piepoli M. et al. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. Int J Cardiol, 2017, vol. 226, pp. 136–140. DOI: 10.1016/j.ijcard.2016.06.083
10. Solomon S.D., Claggett B., Packer M. et al. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail, 2016, vol. 4 (10), pp. 816–822. DOI: 10.1016/j.jchf.2016.05.002. Epub 2016 Jul 6
11. Desai A.S., Solomon S.D., Shah A.M. et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 2019, vol. 322 (11), pp. 1077–1084. DOI: 10.1001/jama.2019.12843
12. Januzzi J.L. Jr, Prescott M.F., Butler J. et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA, 2019, vol. 322 (11), pp. 1085–1095. DOI: 10.1001/jama.2019.12821
13. Nebieridze D.V. Topical issues of the use of beta-blockers in various clinical situations. Meditsinskiy sovet, 2018, vol. 12, pp. 12–17 (in Russ.). DOI: 10.21518/2079-701X-2018-12-12-17
14. Chandra A., Lewis E.F., Claggett B.L. et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol, 2018, vol. 3 (6), pp. 498–505. DOI: 10.1001/jamacardio.2018.0398